#United States #New York #Securities Fraud #Neffy #ARS Pharmaceuticals

ARS Pharmaceuticals Under Investigation After Major Stock Decline

In a dramatic turn of events, investors in ARS Pharmaceuticals (NASDAQ: SPRY) saw an alarming dip in their stock value by over 23% in a single after-hours trading session on June 24, 2026. This sharp decline was precipitated by the company's announcement regarding its product Neffy®, which failed to secure any new commercial formulary additions during the July 2026 payer review cycle, a result that stood in stark contrast to the executives' earlier optimistic projections.

The Background

During its Q4 2024 earnings call held on March 20, 2025, CEO Richard Lowenthal projected an optimistic outlook, suggesting that over 80% of Neffy's prior authorizations would be approved by early summer with the hopes that it would be added to the Caremark formulary. Furthermore, Chief Commercial Officer Eric Karas asserted a target for Neffy to achieve more than 60% commercial coverage by the end of Q1 2026. However, the results from the recent July 1, 2026, review cycle proved otherwise, as not a single new formulary addition was recorded.

Additionally, in an April 29, 2026 filing, ARS Pharmaceuticals maintained that the company had surpassed 90% overall commercial coverage, claiming continued progress toward broad and unrestricted access. Notably absent from this communication was any mention of potential setbacks in the subsequent formulation review process—an omission that would soon emerge as a pivotal issue.

Immediate Repercussions

When the news broke regarding Neffy's lack of advancements in formulary coverage, ARS Pharmaceuticals' stock experienced a significant dive, plummeting by over 23% in after-hours trading. This swift decline indicated a stark revaluation of the company’s commercial prospects, leaving shareholders reeling from substantial financial losses.

Shareholders affected by the downturn are now encouraged to assess their legal rights, especially those who acquired SPRY stock but suffered losses amidst these unforeseen developments. Many may not be aware of their potential eligibility for participation in an ongoing investigation into securities fraud involving ARS Pharmaceuticals. Investors are directed to provide their information to seek clarity on their legal standing.

Dissecting the Allegations

The core of the investigation centers around whether the executives at ARS Pharmaceuticals misled investors by making materially false or misleading statements regarding Neffy®'s commercial coverage projections. Specific claims about CVS Caremark formulary placements and the anticipated timelines for achieving commercial coverage are now under scrutiny, especially as the company failed to deliver on promises during the July payer cycle.

Investigative Process

For investors eager to participate in this investigation, certain documentation will be necessary, including brokerage statements that illustrate their purchase dates, the quantities of stock bought, prices, and any subsequent sale information. It is crucial to understand that eligibility hinges on incurred financial losses, independent of whether the investors continue to hold their shares. Moreover, individuals who sold when the stock was at a loss are still permitted to join the investigation.

Legal Insight

Engaging with Levi & Korsinsky, LLP, the firm spearheading the investigation, involves no initial fees or retainer costs, as the process operates on a contingency basis. An attorney will conduct a free assessment of each client’s trading history to evaluate their potential for recovery, offering clarity in what can often feel like a chaotic and opaque financial landscape.

Final Thoughts

As investigations unfold, it remains crucial for shareholders to stay informed and proactive concerning their rights amidst the complexities of stock market fluctuations and corporate statements. The outcome of this investigation may lead to significant financial reparations for those adversely affected by ARS Pharmaceuticals' recent disclosures, marking a noteworthy chapter in securities and investment transparency.

In light of these events, stakeholders and potential investors are advised to monitor the developments closely, as the repercussions for ARS Pharmaceuticals could have lasting implications on its reputation and share value moving forward.